SCHEMBL1884773

SCHEMBL1884773

[CH2][C@@H](CNC(=O)OC(C)OC(=O)CCC)c1ccc(Cl)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.40
TSHR P16473 3/20 0.38
ALDH1A1 P00352 3/20 0.38
CYP1A2 P05177 2/20 0.38
CYP3A4 P08684 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
MAPK1 P28482 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37
UTS2R Q9UKP6 1/20 0.35
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
RAB9A P51151 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 2/20 0.33
TP53 P04637 2/20 0.33
COMT P21964 1/20 0.33
HSD17B10 Q99714 1/20 0.33
FFAR2 O15552 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1884726 1.00 MAPT (0.40) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1891741 0.84 MAPT (0.42) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1884906 0.84 MAPT (0.42) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1888752 0.83 L3MBTL1 (0.41) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1884157 0.83 L3MBTL1 (0.41) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL2231576 0.83 GABBR2 (0.44) MAPTTSHRCYP1A2CYP3A4CYP2C9
SCHEMBL1890710 0.82 MAPT (0.41) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1886106 0.82 MAPT (0.41) MAPTTSHRALDH1A1CYP1A2CYP3A4
SCHEMBL1884728 0.79 KMT2A (0.35) TSHRALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL9129883 0.77 MAPT (0.54) MAPTALDH1A1CYP1A2CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7935686-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2011-05-03 US disclosed
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use XENOPORT, INC. (US) 2009-05-14 US disclosed
US-7494985-B2 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. (US) 2009-02-24 US disclosed
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use XENOPORT, INC. 2006-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060111325-A1 Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use APEH, AASDHPPT, AGPS MAPT 4107/4885TSHR 1921/4885ALDH1A1 2138/4885
US-20090124582-A1 Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use APEH, AASDHPPT, AGPS MAPT 4107/4885TSHR 1921/4885ALDH1A1 2138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.